ExThera Medical Corporation
ExThera Medical Corporation has developed a broad-spectrum, extracorporeal pathogen filter for treating bloodstream infections. The Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) has CE Mark pending for treating bloodstream infections in adjunction to antibiotic therapy. Seraph 200 was the sole device chosen for GLP safety and efficacy testing in a competitive DARPA program, (Dialysis-Like Therapeutics) successfully removing several drug-resistant bacteria. Located in the San Francisco Bay area, and in Vaals The Netherlands, the company is led by an experienced team .